

Please delete the paragraph on page 11, lines 11-15, and replace it with the following paragraph:

FIG. 2 shows the base sequence of DNA (SEQ ID NO: 2) encoding the human brain-derived protein (SEQ ID NO: 1) (AQ27) of the present invention obtained in Example 1, and the amino acid sequence deduced from the base sequence (continued from Figure 1).

REMARKS

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date January 31, 2003

By Dianne Rees

EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, Massachusetts 02209
Telephone: (617) 439-4444
Facsimile: (617) 439-4170

Dianne M. Rees, Ph.D.
Attorney for Applicant
Registration No. 45,281

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 04-1105 for any such fees; and applicant(s) hereby petition for any needed extension of time.

MARKED UP VERSION ATTACHED TO AMENDMENT IN

SERIAL NO. 10/070,241

Marked up version of the paragraph on page 11, lines 6-10, is below:

FIG. 1 shows the base sequence of DNA **(SEQ ID NO: 2)** encoding the human brain-derived protein **(SEQ ID NO: 1)** (AQ27) of the present invention obtained in Example 1, and the amino acid sequence deduced from the base sequence (following to Figure 2).

Marked up version of the paragraph on page 11, lines 11-15, is below:

FIG. 2 shows the base sequence of DNA **(SEQ ID NO: 2)** encoding the human brain-derived protein **(SEQ ID NO: 1)** (AQ27) of the present invention obtained in Example 1, and the amino acid sequence deduced from the base sequence (continued from Figure 1).

BOS2 325275.1

Attorney Docket No. 57127 (46342)
U.S.S.N. 10/070,241
Filed (I.A.): August 24, 2000
Page 2 of 3

4. Amendment directing entry of Paper Copy of Sequence Listing into specification [included in this paper];
5. Statement Accompanying Submission Of Sequence Listing Under 37 C.F.R. § 1.821(g) (included in this paper);
6. A return receipt postcard.

AMENDMENT DIRECTING ENTRY OF SEQUENCE LISTING

At the last page of the specification, please enter the attached paper copy of the Sequence Listing (6 pages) and number the pages as appropriate.

STATEMENT ACCOMPANYING SUBMISSION OF SEQUENCE LISTING

Provided herewith is a Paper Copy of a Sequence Listing for the nucleotide and/or amino acid sequence(s) in this application. Each Sequence has been assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823. An amendment directing entry of the Paper Copy of the Sequence Listing into the specification is provided above.

Applicants further provide a Computer Readable Form (CRF) corresponding to the Paper Copy of the Sequence Listing provided herewith. Pursuant to 37 C.F.R. § 1.821(g), Applicants' agent hereby states that the CRF corresponds exactly to the Paper Copy of the Sequence Listing provided herewith. Applicants' agent further hereby states that the contents of the Paper Copy of the Sequence Listing and CRF do not go beyond the disclosure in the Application as filed and do not introduce new matter.

Attorney Docket No. 57127 (46342)
U.S.S.N. 10/070,241
Filed (I.A.): August 24, 2000
Page 3 of 3

If for any reason, a fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. **04-1105**.

Respectfully submitted,

Date:

July 27, 2002

Dianne M. Rees
Dianne M. Rees, Ph.D.

Reg. No. 45,281
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

Telephone: 617-439-4444
Customer No. 21874